Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi

American Journal of Dermatopathology

Volumn 26, Issue 6, 2004, Pages 452-457

  Kucher, Cynthia ^a   Zhang, Paul J ^a   Pasha, Theresa ^a   Elenitsas, Rosalie ^a   Wu, Hong ^b   Ming, Michael E ^a   Elder, David E ^a   Xu, Xiaowei ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Desmoplastic; Ki 67; Melan a; Melanoma; Nevus; Sclerotic

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; MELAN A;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DESMOPLASTIC MELANOMA; EPITHELIOID CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; PRIORITY JOURNAL; SPINDLE CELL;

ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; NEOPLASM PROTEINS; NEVUS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 11444251709     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200412000-00002     Document Type: Article

References (28)

1. Conley J, Letterly R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914-936.
2. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003;25:423-428.
3. Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995;32:717-725.
4. Longacre TA, Egbert BM, Rouse RV Desmoplastic and spindle-cell malignant melanoma. An immunohistochemical study. Am J Surg Pathol. 1996;20:1489-1500.
5. Harris GR, Shea CR, Horenstein MG, et al. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. Am J Surg Pathol. 1999;23:786-794.
6. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139-146.
7. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J. 2000;32:475-481.
8. Boyle J, Haupt H, Stern J, et al. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med. 2002;126:818-822.
9. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase n the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196-200.
10. Xu X, Chu A, Pasha T, et al. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26:82-87.
11. Jungbluth A, Busam K, Gerald W, et al. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602.
12. Riccioni L, Di Tommaso L, Collina G. Actin-rich desmoplastic malignant melanoma: report of three cases. Am J Dermatopathol. 1999;21:537-541.
13. Busam K, Chen Y, Old L, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
14. Key G, Becker MH, Baron B. Preparation and immunobiochemical characterization of new Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against recombinant parts of the Ki-67 antigen. Anal Cell Pathol. 1992;4:181-186.
15. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol. 1989;11:301-307.
16. Rieger E, Hofmann-Wellenhof R, Soyer HP, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol. 1993;20:229-236.
17. Rudolph R, Schubert C, Schubert B, et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol. 1997;37:169-178.
18. Kanter L, Blegen H, Wejde J, et al. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties. Melanoma Res. 1995;5:345-350.
19. Sparrow LE, English DR, Taran JM, et al. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol. 1998;20:12-16.
20. Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001;145:203-209.
21. Soyer HP. Ki67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol. 1991;18:264-272.
22. Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Histopathology. 1999;34:517-525.
23. Martinez-Arribas F, Nunez MJ, Piqueras V, et al. Flow cytometry vs. Ki67 labeling index in breast cancer: a prospective evaluation of 181 cases. Anticancer Res. 2002;22:295-298.
24. Kaleem Z, Lind A, Humphrey P, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol. 2000;13:217-222.
25. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44:500-504.
26. Li LX, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489-495.
27. Moretti S, Massobrio R, Brogelli L, et al. Ki 67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol. 1990;95:183.
28. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol. 2002;26:654-661.